Literature DB >> 2715366

An interindividual variability in the sensitivity of atrioventricular node to diltiazem in patients with paroxysmal supraventricular tachycardia.

S Fukuhara1, H Echizen, M Naito, S Ishikawa, M Toyama, H Nagoshi, M Honda, T Ishizaki.   

Abstract

To study the sensitivity of atrioventricular (AV) node to diltiazem in seven patients with paroxysmal supraventricular tachycardia (PSVT), we analyzed the plasma concentration-response relationship of this Ca-antagonist using AH interval as an index for assessing its Ca channel blocking effect on the AV node after an IV infusion (0.4 mg/kg). The postdose AH intervals were prolonged compared with the baseline, and their percentage changes correlated significantly (P less than 0.01) with log-diltiazem concentrations in all patients. However, drug concentrations associated with a 20% prolongation of AH interval differed considerably among the patients (range; 65 to 260 ng/ml), indicating a large interindividual variability in the sensitivity of AV node to diltiazem. These results suggest that the interindividual difference in the responsiveness of AV node to diltiazem-induced Ca channel blocking effect may be one of the possible explanations for the therapeutic failure of this Ca-antagonist for terminating PSVT or preventing its recurrences in certain patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2715366     DOI: 10.1002/j.1552-4604.1989.tb03294.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  2 in total

1.  Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors:  Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

2.  Prolongation of the PQ interval as a measure of therapeutic inequivalence between two formulations of diltiazem.

Authors:  O E Della Paschoa; V Luckow; D Trenk; E Jähnchen; S R Santos
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.